The expanded service offering is available in both of the company's Lincoln and Zürich bioanalytical laboratories and includes ELISpot analysis, flow cytometry, and qPCR.
Celerion's expanded service offering provides platforms for immune monitoring and biomarker screening with high-throughput flow cytometry and ELISpot testing.
Celerion has a pre-qualified interferon gamma ELISpot assay, allowing for a significantly faster validation process with study-specific antigens, thereby accelerating the development process for cell and gene therapies and vaccines alike.
Celerion also supports vaccine development programs by offering fully automated ELISA assays in a Biosafety Level 2 environment.
Flow cytometry is used to support the drug development of cell, gene, and immunotherapies with endpoints including immune-phenotyping of immune cells and receptor occupancy assessment.
Celerion also provides high-throughput molecular biology testing for vector shedding analysis for gene therapies in compliance with current regulations as well as biodistribution to support GLP studies and transgene expression analysis using RT-PCR.
Farmen adds that Celerion has decades of regulatory experience, scientific excellence, and laboratory investments that enable accelerated development of these complex therapies.
Celerion is a specialist in early clinical research services.
ZyVersa Therapeutics names new independent board members
Abintus Bio Names Hebrew University Researcher Lior Nissim as Head of Synthetic Biology
hVIVO wins GBP5.2m contract for RSV vaccine trial
Spear Bio announces expansion of NAB-Sure Neutralizing Antibody Test Kit product line
Novavax announces Phase 2 trial of combined vaccine for COVID-19 and influenza
Valneva completes US regulatory filing for chikungunya vaccine candidate